Deep-learning model that estimates a patient's 10-year risk of major adverse cardiovascular events (MACE) directly from a single routine chest radiograph (CXR), intended as an opportunistic risk-assessment tool when the inputs needed for the standard ASCVD risk calculator (lipids, blood pressure, smoking status, etc.) are missing. A 2D convolutional network takes the CXR image alone as input and outputs a continuous 10-year MACE risk estimate. Developed on 147,801 CXRs from 40,718 participants in the PLCO cancer-screening trial and externally validated in 8,869 outpatients with unknown ASCVD risk and 2,132 with known risk at Mass General Brigham, CXR CVD-Risk identified people at elevated MACE risk (adjusted hazard ratio 1.73 for a >=7.5% predicted risk) and provided added discrimination beyond the traditional ASCVD score.

Multi-outcome AI-ECG risk-estimation platform that turns a single 12-lead ECG into a patient-specific survival curve, using a residual convolutional neural network trained with a discrete-time survival loss to predict not just risk but time-to-event. Beyond all-cause and cardiovascular mortality, separately fine-tuned heads predict future ventricular arrhythmia, complete heart block, atrial fibrillation, atherosclerotic cardiovascular disease, heart failure, and (in follow-up work) hypertension -- all from a single resting ECG, including in ECGs a cardiologist would read as normal. Derived on 1.16 million ECGs from 189,539 Beth Israel Deaconess Medical Center patients and externally validated across transnational cohorts in the USA, Brazil (CODE), and the UK (UK Biobank). A variational autoencoder and genome/phenome-wide association analyses were used to show the model's predictions track biologically plausible features (QRS morphology, LV structure/function, and loci linked to cardiac structure, QT interval, and biological aging). NHS trials of AIRE were planned for late 2025. No public code or model weights have been released.

1D residual neural network that predicts a patient's age directly from a 12-lead ECG; the gap between this predicted 'ECG age' and true chronological age is used as a biomarker of cardiovascular risk and mortality. Trained on the CODE-15% Brazilian ECG dataset, with the original R² of 0.71 later reproduced (R² = 0.70) in an independent German validation cohort. Developed by researchers at Uppsala University and UFMG.

Multi-task 12-lead ECG model with output heads for incident atrial-fibrillation risk (as a survival curve), incident mortality risk, prevalent AF classification, sex classification, and age regression. Built on a 1D CNN over the raw waveform, and developed by the Broad Institute's ML4H group as a successor to their ECG-AI model published in Circulation. Trained on ECGs from UK Biobank and Massachusetts General Hospital, neither of which is publicly released.

Predicts a patient's age from echocardiogram videos across four standard views (PLAX, A2C, A4C, and subcostal), trained on a private multi-site cohort of over 2.6 million videos from more than 166,000 studies across roughly 90,000 patients. The gap between this AI-predicted age and true chronological age is studied as a marker of accelerated or delayed cardiovascular aging and its relationship to all-cause mortality. Uses a 3D CNN (R(2+1)D) with a separate pretrained model per view. Developed by Cedars-Sinai Medical Center and Stanford's Ouyang lab.